AbCellera Biologics Inc.
ABCL
$4.24
-$0.23-5.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -35.41% | -24.17% | -34.59% | -77.23% | -80.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.41% | -24.17% | -34.59% | -77.23% | -80.23% |
| Cost of Revenue | 5.03% | -4.78% | 8.27% | 3.87% | 4.07% |
| Gross Profit | -16.47% | -0.58% | -28.56% | -770.43% | -604.45% |
| SG&A Expenses | 8.90% | 13.72% | 18.93% | 14.26% | 11.54% |
| Depreciation & Amortization | 150.10% | 141.24% | 285.24% | 151.88% | 13.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.25% | 13.21% | 35.91% | 19.47% | 6.94% |
| Operating Income | -27.86% | -19.21% | -53.62% | -149.56% | -250.05% |
| Income Before Tax | -24.91% | -15.15% | -28.90% | -151.93% | -323.06% |
| Income Tax Expenses | -96.79% | -35.85% | 4.79% | -970.72% | -310.88% |
| Earnings from Continuing Operations | -14.28% | -11.24% | -36.13% | -107.42% | -192.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.28% | -11.24% | -36.13% | -107.42% | -192.84% |
| EBIT | -27.86% | -19.21% | -53.62% | -149.56% | -250.05% |
| EBITDA | 3.17% | 10.83% | -24.66% | -148.92% | -363.00% |
| EPS Basic | -12.30% | -9.28% | -33.82% | -105.07% | -190.07% |
| Normalized Basic EPS | -16.14% | -7.15% | -51.65% | -207.96% | -521.44% |
| EPS Diluted | -10.10% | -7.56% | -34.93% | -96.72% | -176.20% |
| Normalized Diluted EPS | -16.14% | -7.15% | -51.65% | -186.09% | -435.54% |
| Average Basic Shares Outstanding | 1.79% | 1.79% | 1.71% | 1.62% | 1.53% |
| Average Diluted Shares Outstanding | 1.79% | 1.79% | 1.71% | -1.01% | -1.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |